The Salk Institute said its sonogenetics team, led by associate professor Sreekanth Chalasani, received $41.3 million from ARPA-H to advance ultrasound-controlled protein therapeutics toward human trials. The five-year effort will develop ultrasound delivery systems and core biological tools, building preclinical evidence for entry into clinical development. Sonogenetics uses low-intensity ultrasound to activate engineered ultrasound-sensitive proteins, aiming for drug-free control over when and where therapy is delivered. Salk also described a wearable ultrasound approach intended to provide cellular and temporal precision.